On Aug. 27, 2020, Myriad RBM announced ultrasensitive immunoassays for viral pneumonia Including COVID-19 from our CLIA-certified laboratory.

Three papers with a concise ‘Perspectives’ piece summarizing the reports were published in the August 7, 2020 issue of Science magazine. The work sheds new light on the importance of Type I (IFN-a & IFN-) and Type III (IFN-? or IL-29) interferons for viral pneumonia including severe COVID-19 disease.